Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This was from the other site.
What a great bunch of people,I had the honor of getting to know.
Winners helping winners
Posted By: James719
Good morning dipper and rippers. Sure appreciate this site and fitzkarz who got it going. I used to be one who focused on one particular stock and one website that promoted that stock and nothing else. All I did was lose money buying on all the "great opportunity" to buy at a lower level. Fitzkarz has really helped me to have a broader perspective with many different stocks and many different perspectives on those stocks. I'm not yet to OSD's perspective on trading and being happy with 10, 20, 30% and sometimes much more. Though his method of trading challenges me to look at another way of trading. Kudos to all who share and challenge me to be better as fitzkarz always did. My best to all, most of all to you, fitzkarz for helping me to get out of a little pond and getting in a much larger pond. Where the perspective is making money, not being one of the crowd losing money and encouraging others to lose money. Jim
Nice, Never go broke taken a profit!
Nice, $MGTI 1.67 0.23 +15.97 759,302 1.66 1.68
Continuation, $ANTH 1.27 0.00 0.00 14,036 1.40 1.45
Huge upside, imo
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
6 minutes ago - DJNF
Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial Network
HAYWARD, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that the RESULT Phase 3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the European Cystic Fibrosis Society Clinical Trial Network (ECFS CTN) Executive Committee. The aim of the ECFS CTN is to intensify clinical research in the area of cystic fibrosis and to bring new medicines to patients as quickly as possible. Enrollment in RESULT, in both the US and EU, is on schedule and inclusion of the study in the ECFS CTN may further expedite patient recruitment for the RESULT clinical study. Topline data are expected at the end of 2017 to early 2018, depending on the speed of patient enrollment.
"We are very pleased to receive approval by the ECFS Executive Committee for inclusion of the RESULT trial in the ECFS CTN," said Craig Thompson, President & CEO of Anthera. "This achievement, in combination with the earlier approval from the Cystic Fibrosis Foundation Therapeutics Development Network, represents another key milestone for the RESULT trial."
The RESULT clinical study design evolved from the data in the previous Sollpura trial (SOLUTION) and allows for more frequent and higher dose adjustments based upon clinical signs and symptoms. As with current practice with porcine enzymes, the RESULT study allows dose increases on an individualized basis to achieve maximum therapeutic benefit, while maintaining a potential reduction in daily pill burden due to Sollpura's significantly more compact formulation technology.
About RESULT
The Phase 3 RESULT study is designed to evaluate the non-inferiority of Sollpura at individualized doses compared to approved, porcine-derived, enteric-coated pancreatic enzyme replacement therapy (PERT) when administered to patients with EPI due to CF. The study will enroll patients (N.APPROX.150) who are well-controlled on stable porcine PERT at screening, as demonstrated by the coefficient of fat absorption (CFA). The primary efficacy variable will evaluate the change from baseline in CFA following 4 weeks of treatment with either Sollpura or Pancreaze. Patients randomized to Sollpura will then be followed for an additional 20-Week extension period (total of 24 weeks on study) for longer term assessments of weight, height, BMI, and safety.
About Sollpura(R) (liprotamase)
Sollpura is a novel, non-porcine PERT containing a proprietary, biotechnology-derived formulation of cross-linked crystalline lipase, crystalline protease, and amorphous amylase with broad substrate specificity, formulated in a precise and fixed ratio to provide stability in acidic pH environments, like that found in the stomach, without enteric coating. Being non-porcine, Sollpura mitigates porcine-associated risks including supply limitations and the potential for contamination with pig-associated viral or other infectious agents. In addition, given its stability in the absence of enteric coating, a soluble, drinkable formulation of Sollpura is in development, which may provide an easy-to-administer option especially for pediatric patients and patients who receive their nutrition through feeding tubes.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on Anthera can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact Information
CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com
For Media Inquiries:
Frannie Marmorstein
rbb Communications
frannie.marmorstein@rbbcommunications.com
305-567-0821
www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
(END) Dow Jones Newswires
August 14, 2017 08:30 ET (12:30 GMT)
Little love, Maybe. $ZSAN 0.85 0.00 0.00 20,500 0.90 0.92
BIOC 1.25 0.00 0.00 26,711 1.37 1.39
Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
21 minutes ago - DJNF
Patented blood collection tubes developed by Biocept validated to preserve ctDNA for up to 96 hours at room temperature allowing for intact shipping of liquid biopsy samples from regions around the world
SAN DIEGO, Aug. 14, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has signed an exclusive global Distribution Agreement excluding China, for the Company's proprietary blood collection tubes (BCTs) with VWR International, LLC (VWR), the leading global independent provider of product and service solutions to laboratory and production customers. Biocept's BCTs allow for the intact transport of liquid biopsy samples for research use only from regions around the world. Commercial launch is anticipated to begin in the second half of 2017.
The patented BCTs were developed at Biocept, and, over the past four years, have been used to transport thousands of patient samples containing both circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). Specimen types successfully transported with this technology include blood, cerebrospinal fluid, sputum, and fluid obtained from pleural effusion. Use of the Company's BCTs does not require pre-shipment specimen processing, refrigeration during shipping, or centrifugation upon receipt, which can be barriers to the adoption of liquid biopsy. Study data demonstrating the ability to successfully collect and preserve patient blood samples for use with single gene tests and a broad liquid biopsy panel were presented in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in April.
"Our patented blood collection tubes are designed to facilitate the high-growth potential of liquid biopsy, and our agreement with VWR can help us leverage this opportunity in scale," said Mike Terry, Senior Vice President, Commercial Operations. "Collection and preservation of patient samples are key requirements to perform liquid biopsy, and given our historic use of these tubes for the transport and preservation of many liquid biopsy specimens, we believe that our BCTs offer a clinically robust solution."
Michael Nall, Biocept's President and CEO, added, "We are very proud to be working with VWR, for the distribution of our proprietary liquid biopsy collection tubes. Entering into the global market with a scaled offering for liquid biopsy is the first step toward growing from an exclusive CLIA lab business to a technology and products company. The development of this important technology is a prime example of how Biocept intends to leverage its proprietary technologies and intellectual property to improve the standard of care for cancer patients and to increase the value of our Company for shareholders."
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector(TM) liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe, " "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, increase revenue or sales, the utility and effectiveness of our intellectual property protections, and our ability to drive additional value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov.
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-exclusive-distribution-agreement-with-global-laboratory-product-supplier-vwr-300503561.html
SOURCE Biocept, Inc.
/CONTACT: Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100; Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109
/Web site: http://www.biocept.com
(END) Dow Jones Newswires
August 14, 2017 08:05 ET (12:05 GMT)
This was my reply message to the games on the other site.
By email, because my IP was already block!
Army, where are you buddy?
Person marked!
Thank you, For all your great plays. That i have profited from!
Thanks again for all your DD and great plays.
https://investorshub.advfn.com/Nasdaq-Dip-&-Rip-32462/
Morning all, Great day!
I'm holding a milly, for a lotto play. Fingers crossed curly!
I think this will work out great.
Thanks for your support!
Don’t Let Your Ego Hijack Your Leadership Effectiveness
https://www.fastcompany.com/1840932/dont-let-your-ego-hijack-your-leadership-effectiveness
Just starting here, but please hit follow board.
Thanks fitz!
New board created today, Everyone is welcome!
Thanks$ONCI added to watch list!
$CHMA 1.8554 0.4554 +32.53 867,597 1.80 1.90
$CHMA 1.80 0.40 +28.57 377,550 1.75 1.80
$CHMA 1.62 0.22 +15.71 73,401 1.60 1.65
$AEZS 2.0668 0.3368 +19.47 496,751 2.04 2.07
( AEZS ) Investor Network: Aeterna Zentaris Inc. to Host Earnings Call
2 hours 48 minutes ago - DJNF
NEW YORK, NY / ACCESSWIRE / August 11, 2017 / Aeterna Zentaris Inc. (NASDAQ: AEZS) will be discussing their earnings results in their Q2 Earnings Call to be held on Friday, August 11, 2017 at 8:30 AM Eastern Time.
To listen to the event live - visit: https://www.investornetwork.com/company/23335
Replay Information
The replay will be available online at: https://www.investornetwork.com/company/23335
About Investor Network
Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.
SOURCE: Investor Network
(END) Dow Jones Newswires
August 11, 2017 07:01 ET (11:01 GMT)
Morning movers,$AEZS $AMRS $CHMA $MNKD
Also $TOPS becareful!
Thanks, If you could let others know in private.
It would be greatly appreciated, Thanks again!
Hi mac, Happy to see you here. I like Pharma stocks.
We will becoming more active here.
Winners help winners!
To anyone looking in, This will be my new home.
Soon as i get my act back together!
Not much, No longer with the other site.
When people make decisions with there ego and greed.
The end is near, IMO
I will be around for now!
Good morning Sheepwolf, Hope all is well!
Good morning Depcom, Hope all is well.
I will be spending more time around here, for now on!
In my prayers buddy for you and your family!
Yep, Still laughing with $ELFN profits over 100%
Who bought the 3.2m sells of $EFLN?
Now this is funny,
Shaumus, How you been? Happy $EFLN is moving up!
put it on watch list first, $GNAU add. Don't click the pop up, just hit add.
Then place your order from that!
Solid close, Go $SDVI
Nice, Thanks for the $SDVI money play sheep. Bought @ .0004 & .0005
I agree, Go $PVCT
Hey Sheepwolf, person marked. Just checking out whats happening!
$PVCT, Slow and steady. Nice!